COV2Base-A Rare Disease by COVID Study

Natural History Study: COV2Base-a Rare Disease by COVID Study

Background:

SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a role in the severity of COVID. In this study, researchers want to assess sociodemographic-, population-, disease-, and gene-based risks for features associated with severe SARS-CoV-2 outcomes. As more is understood about COVID, researchers also want to learn more about people s experiences with COVID vaccines, long-haul symptoms, and other related disease features.

Objective:

To measure the frequency and severity of COVID infection in people with rare and common diseases, looking for conditions that increase risk of severe outcomes. To describe experiences with COVID vaccines, symptoms, and other features of COVID in people with rare and common diseases.

Eligibility:

People greater than 1 month of age, both with and without rare disease, who have access to the Internet.

Design:

This study will take place online.

Participants will visit a website. They will fill out a survey. It should take less than 30 minutes to complete. They will answer questions about their current health and COVID experiences. They will answer questions about their demographic and location features that may impact their exposure to the virus. All questions are optional.

Participants may repeat the survey if their responses indicate a need for follow-up.

Participants medical records may be reviewed.

Participants may be contacted for future studies related to:

COVID

Their underlying health conditions

A new exposure that is being studied....

Study Overview

• Status: Completed
• Conditions: Chronic Health Conditions; Older Age is Associated With Increased Pathogenicity

Detailed Description

Study Description:

This protocol will collect information on frequency and severity of COVID infection for patients with rare diseases and community controls.

Study Objectives:

Primary Objective: To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.

Secondary Objective: To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies.

Tertiary Objective (exploratory): To investigate the role of pre- existing disease- or socioeconomic- factors that contribute to COVID- related stress and to evaluate whether individuals with the conditions studied experience more extreme symptoms around the time of COVID vaccine.

Endpoints:

Primary Endpoint: Frequency of severe infection (hospitalization +/- ICU stay and/or COVID-related death) secondary to COVID in patients with a shared disease designation.

Secondary Endpoint: Frequency of severe infection (hospitalization +/- ICU stay and/or COVID-related death) secondary to COVID in patients with shared organ system involvement, secondary comorbidities, or sociodemographic differences.

AND Frequency of any infection or symptoms (including long haul symptoms) secondary to COVID in study patients as grouped by genetic diagnosis, organ system involvement, secondary comorbidities, or sociodemographic features.

Tertiary Endpoints (exploratory): Frequency and degree of COVID related stress based on pre-existing disease-, organ system-, or socioeconomic- factors and frequency of extreme symptoms following one of the COVID vaccines based on pre-existing disease-organ system-, or socioeconomic- factors.

Study Population:

The study will include people greater than 1 month old, with and without rare disease. Some members of the study population have cognitive impairment on the basis of their rare disease.

Description of Sites/Facilities Enrolling Participants:

All consent and study procedures/questionnaire will be performed online.

Study Duration:

The study will enroll for up to 13 months.

Participant Duration:

After consent, participants (or their legal authorized representative) will be asked to fill out an online questionnaire that should take <30 minutes. We may re-send the survey to the participants in 6 - 12 months. Filling out the second round questionnaire is preferred but not required. New enrollees at the time the 2nd questionnaire is sent will fill out the questionnaire once at Time 2. If a signal for increased symptoms is identified in one or more studied groups, individuals from that group may be re-contacted with additional questions or request for medical records within the 13 month window. Participants will be consented for re-contact.

• Study Type: Observational
• Enrollment (Actual): 1748

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Bethesda, Maryland, United States, 20892
      • National Heart, Lung and Blood Institute (NHLBI)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Study groups (those being reported upon) include those with known rare medical conditions and those without (community populations). Some individuals being reported on may be children or those with cognitive impairment.

Description

• INCLUSION CRITERIA:

The person being reported upon must be 1 month of age or older. The reporter must have access to the internet and be able to read and answer questions in English or Spanish.

EXCLUSION CRITERIA:

Individuals unwilling to allow sharing of their research data should not participate. With the use of online consents for large numbers of individuals, opting in or out of sharing for this low risk study creates a burden for this research study as well as the ability to share data with other related research studies for meta-analysis.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Other

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
1; patients with rare and common diseases

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.	To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies.	To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies.	13 months

Collaborators and Investigators

• Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Study record dates

Study Major Dates

• Study Start (Actual): October 4, 2020
• Primary Completion (Actual): May 20, 2022
• Study Completion (Actual): May 20, 2022

Study Registration Dates

• First Submitted: September 24, 2020
• First Submitted That Met QC Criteria: September 24, 2020
• First Posted (Actual): September 25, 2020

Study Record Updates

• Last Update Posted (Actual): January 20, 2023
• Last Update Submitted That Met QC Criteria: January 19, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Natural History; Precision Medicine; Modifier of Disease; Common Diseases; Increase Risk of Severe Outcomes; Gene-Based Risk
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Rare Diseases
• Other Study ID Numbers: 10000091; 000091-H

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No